Inclusion Criteria:  Patients receiving care at a University Hospitals location Patients 40-89 year of age Diagnosis of Type 2 Diabetes Mellitus Eligible for but not currently prescribed a SGLT2i or GLP1RA per drug label. This includes a diagnosis of type 2 diabetes plus established atherosclerotic cardiovascular disease or high risk for atherosclerotic cardiovascular disease (including age ≥55 years with coronary, carotid, or lower-extremity atherosclerotic disease) or heart failure or chronic kidney disease with or without albuminuria. Patients that are able to provide consent  Exclusion Criteria:  Intolerance or contraindication for use of both GLP1RA and SGLT2i Use of SGLT2i or GLP1RA within the 3 months prior to enrollment History of, an active, or untreated malignancy, in remission from a clinically significant malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years prior to, or are receiving or planning to receive therapy for cancer, at screening Patients that have Systemic Lupus Erythematous (SLE) End-stage renal disease Pregnancy (as determined by self-report) Inability to understand English (since must be able to understand risk report which is not translated by the manufacturer)